Karyopharm Therapeutics

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Karyopharm reports robust revenue growth and strategic clinical advancements

Karyopharm Therapeutics demonstrated strong performance in revenue growth and clinical pipeline advancements, positioning them for continued success in 2023.
Strategic strengths in product portfolio, leadership, and innovation align well with opportunities in accelerating growth and exploring novel treatment approaches.
Challenges in differentiation, data updates, and dose optimization require focused strategies to overcome obstacles and drive sustainable growth.
Overall, Karyopharm's focus on patient outcomes, strategic expansion, and upcoming milestones indicate a positive trajectory for the company.

Karyopharm Therapeutics navigates revenue challenges while advancing pipeline innovations

Karyopharm Therapeutics faced revenue challenges due to PAP usage and discounts but showcased strong demand for XPOVIO and promising pipeline progress.
The company's financial stability was supported by expense reductions and total revenue of $38.7 million for Q1 2023.
Opportunities lie in commercial expansions, Phase III data advancements, and strategic product development efforts, positioning Karyopharm for future growth and innovation.

Karyopharm Therapeutics excels in Q2, eyes $2B peak revenues

Karyopharm Therapeutics showcased strong financial performance, strategic workforce reductions, and progress in pivotal Phase III trials during the Q2 earnings call. The company's focus on advancing novel SINE compounds and maintaining financial strength positions them well for future growth and value creation.

Karyopharm Therapeutics reports robust Q3 earnings and highlights growth prospects

Karyopharm Therapeutics showcased strong financial performance with revenue of $36 million and emphasized growth potential.
Promising Phase III trial data for myelofibrosis and endometrial cancer positions selinexor as a treatment paradigm changer.
Challenges include PAP impact from foundation closures, but opportunities lie in novel drug combinations and growth strategies.

Karyopharm meets revenue targets, eyes transformative outcomes in trials

Karyopharm Therapeutics delivered on revenue targets, showcasing strong performance and promising trial results in key indications.
While facing challenges in academic settings and financial obligations, the company's strategic strengths and growth opportunities position it well for the future.
With a focus on advancing Phase III trials, leveraging IP advantages, and exploring new treatment avenues, Karyopharm aims for continued innovation and market expansion.
Overall, Karyopharm's Q4 2023 Earnings Call reflects a balanced outlook with a solid foundation for growth and value creation in the biopharmaceutical sector.

Karyopharm Therapeutics reports strong Q1 performance and strategic refinancing

Karyopharm Therapeutics' Q1 2024 earnings call highlighted robust performance, strategic refinancing, and promising late-stage pipeline developments. While facing challenges in financial clarity and trial progress, the company is well-positioned to capitalize on growth opportunities through biomarker-driven patient selection and combination therapies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

NEWTON, Mass., July  20, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) seeking approval for XPOVIO® (selinexor), its first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with multiple myeloma after at least one prior line of therapy.  Karyopharm expects a decision from the FDA regarding this sNDA before the end of the first quarter of 2021.

U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

Karyopharm has a market cap under $1.5 billion, yet peak sales of Xpovio in just its first 3 indications could easily exceed that figure.

Karyopharm Is Trading At A Discount After Recent Additional Xpovio Approval

Karyopharm's XPOVIO Progress And Other News: The Good, Bad And Ugly Of Biopharma

NEWTON, Mass., July  17, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program (CTEP). The CRADA will focus on advancing XPOVIO (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, which blocks the cellular protein XPO1. XPO1 plays a key role in regulating the activity of tumor suppressor proteins and other oncoproteins relevant in cancer cell biology and cancer cell survival. XPO1 may be an important, novel target in the treatment of numerous  cancer types. XPO1 is frequently overexpressed in both hematologic and solid tumors, and the degree of XPO1 over-expression correlates with higher tumor grade and poor overall patient survival.

Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research

-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the  Second Quarter 2020 --   -- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch --

Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)

Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity

NEWTON, Mass., June  24, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating XPOVIO in patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) were published  online in   The Lancet Haematology  . The SADAL study evaluated selinexor, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound for the treatment of adult patients with RR DLBCL, not otherwise specified, who have received at least two prior therapies.  

Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL

Aridis Pharmaceuticals

Canopy Growth

Deutsche Bank

Darden Restaurants

HSBC Holdings

NIKE

UBS Group AG

Zogenix

The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week.

8 Stock Catalysts For The Week Ahead (June 22)

-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular Lymphoma --    -- XPOVIO is the First and Only FDA-Approved Drug for Use in Both Multiple Myeloma and DLBCL --

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

-- Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary Refractory Disease and Regardless of Number of Prior Therapies -- -- Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary Refractory Disease and Regardless of Number of Prior Therapies --

Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting

Karyopharm (KPTI) commences a phase I/II study evaluating Xpovio (selinexor) in combination with standard-of-care therapy in patients with newly-diagnosed or recurrent glioblastoma.

Karyopharm Starts Dosing in Selinexor Study for Glioblastoma

NEWTON, Mass., June  09, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patients with newly diagnosed or recurrent glioblastoma (GBM). This global study is expected to enroll approximately 400 patients at clinical sites in the U.S., Europe, and Israel.

Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Karyopharm Therapeutics (KPTI) Stock?

NEWTON, Mass., June  01, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,800 shares of Karyopharm’s common stock to seven newly-hired employees, with a grant date of May 29, 2020.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Karyopharm Therapeutics  Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

--  Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd)  --    -- SVd Was Superior to Vd Across Key Secondary Efficacy Endpoints Including Overall Response Rate, Percent of Patients Achieving  ≥ VGPR and Median Duration of Response --

Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

NEWTON, Mass., May  20, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOVIO® (selinexor), its first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with previously treated multiple myeloma.

Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

KPTI Has sNDAs In Process That Could More Than Double Its Share Price If Approved

NEWTON, Mass., May  13, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19 pandemic including cancer patients, their families, and the healthcare workers caring for them. Karyopharm will donate masks to Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society®, three prominent organizations focused on the well-being of cancer patients, to improve the safety and security of the broader cancer community.

Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and  The Leukemia & Lymphoma Society

Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q1 2020 Results - Earnings Call Transcript

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) fell 9% in pre-market trading after the company reported Q1 results.

Recap: Karyopharm Therapeutics Q1 Earnings

Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Karyopharm (KPTI) Might Surprise This Earnings Season

NEWTON, Mass., May  01, 2020  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 74,800 shares of Karyopharm’s common stock to 15 newly-hired employees, with a grant date of April 30, 2020.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Karyopharm  Therapeutics  Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

-  A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study -

Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

News for Karyopharm Therapeutics Stock (KPTI)